{
    "nct_id": "NCT03933670",
    "official_title": "A Phase 2 Study of Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) in Patients with Prostate Cancer on Active Surveillance",
    "inclusion_criteria": "* The subject has biopsy-proven adenocarcinoma of the prostate with low to intermediate risk disease by UCSF-CAPRA scoring at study entry.\n* For Part 1: Patient planning to enroll or currently on active surveillance; For Part 2: Currently enrolled on active surveillance with planned fusion biopsy within 12 weeks following completion of baseline HP C-13 pyruvate/mpMRI on study.\n* The subject is able and willing to comply with study procedures and provide signed and dated informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Absolute neutrophil count (ANC) >= 1000 cells/microliter (uL).\n* Hemoglobin >= 9.0 gm/deciliter (dL).\n* Platelets >= 75,000 cells/uL.\n* Estimated creatinine clearance* >= 50 milliliter (mL)/min by the Cockcroft Gault equation.\n* Total bilirubin =< 1.5 x upper limit of normal (ULN) or if =< 3 x ULN if known/suspected Gilbert's\n* Aspartate aminotransferase (AST) =< 1.5 x ULN.\n* Alanine aminotransferase (ALT) =< 1.5 x ULN.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients without evidence of any prostate cancer on most recent prostate biopsy performed prior to study entry.\n* Current or prior androgen deprivation therapy including luteinizing hormone-releasing hormone (LHRH) analogue or oral anti-androgen therapy. Previous use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least 28 days prior to baseline C-13 HP pyruvate MRI\n* Prior radiation treatment of the prostate.\n* Prostate biopsy performed within 14 days prior to baseline C-13 HP pyruvate MRI.\n* Poorly controlled hypertension, with blood pressure at study entry > 160 mm Hg systolic or > 100 mmg Hg diastolic. Treatment with anti-hypertensives and re-screening is permitted.\n* Congestive heart failure with New York Heart Association (NYHA) status >= 2.",
    "miscellaneous_criteria": ""
}